The goal of this study is to enroll 250 participants that have joined the MURDOCK Study
Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND
current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page
questionnaire designed to collect information on the diagnosis of severe acne and response to
oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne
vulgaris and the outcome of oral isotretinoin treatment.